National MAPD/PDP Prescription Benefit Design Conjoint Study

Publishes January 13, 2023 | Senior Market

With prescription drug formulary, cost, and delivery structure remaining as the dominant factors in overall selection criteria, this year’s national conjoint study will help product developers design a drug benefit that drives the most value — whether embedded in MAPD plans or as a stand-alone PDP offering.

INCLUDED WITH EVERY STUDY

In-Depth Market Research Studies
Insightful data, charts, and commentary are included with each study. Reports range from 75 to 100 slides.

Expert Presentations
Deft’s experts bring each study to life through a live presentation.

Engaging Videos
With every SMIS study, get access to a full-length Deft on Demand video presentation and Executive Summary at no additional cost.

Custom Analysis
Every study comes with up to three hours of additional analyst time to provide custom views of the data.